India’s burgeoning fertility care industry is preparing for a high-profile wave of public offerings, with Indira IVF taking the lead by filing its draft red herring prospectus (DRHP) for an initial public offering. The move underscores growing investor appetite for specialized healthcare services amid rising demand for assisted reproductive treatments. Meanwhile, Gaudium IVF is also charting a course toward the capital markets, hinting at an imminent IPO filing.